Asoprisnil

Asoprisnil
Systematic (IUPAC) name
	rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17-
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	199396-76-4
ATC code	None
PubChem	CID 9577221
ChemSpider	7851660
UNII	72W09924WP
KEGG	D02996
ChEMBL	CHEMBL267431
Chemical data
Formula	C28H35NO4
Mol. mass	449.582 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1 ; Key:GJMNAFGEUJBOCE-MEQIQULJSA-N ;
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata.^[1]

In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.^[2]

[edit] References

^ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
^ Schering Interim Report Q1-3 2005

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.